|
1
|
Tang S, Wang K, Zheng K, Liu J, Zhang H,
Tan M, Li H, Li H, Tan X, Liu D and Guo R: Clinical and
pathological response to neoadjuvant chemotherapy with different
chemotherapy regimens predicts the outcome of locally advanced
breast cancer. Gland Surg. 9:1415–1427. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Golshan M, Loibl S, Wong SM, Houber JB,
O'Shaughnessy J, Rugo HS, Wolmark N, McKee MD, Maag D, Sullivan DM,
et al: Breast conservation after neoadjuvant chemotherapy for
triple-negative breast cancer: surgical results from the brightness
randomized clinical trial. JAMA Surg. 155:e1954102020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yu KD, Ye FG, He M, Fan L, Ma D, Mo M, Wu
J, Liu GY, Di GH, Zeng XH, et al: Effect of adjuvant paclitaxel and
carboplatin on survival in women with triple-negative breast
cancer: A phase 3 randomized clinical trial. JAMA Oncol.
6:1390–1396. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kumar H, Gupta NV, Jain R, Madhunapantula
SV, Babu CS, Kesharwani SS, Dey S and Jain V: A review of
biological targets and therapeutic approaches in the management of
triple-negative breast cancer. J Adv Res. 54:271–292. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yuan P, Hu X, Sun T, Li W, Zhang Q, Cui S,
Cheng Y, Ouyang Q, Wang X, Chen Z, et al: Eribulin mesilate versus
vinorelbine in women with locally recurrent or metastatic breast
cancer: A randomised clinical trial. Eur J Cancer. 112:57–65. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cortes J, O'Shaughnessy J, Loesch D, Blum
JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V,
Delozier T, et al: Eribulin monotherapy versus treatment of
physician's choice in patients with metastatic breast cancer
(EMBRACE): A phase 3 open-label randomised study. Lancet.
377:914–923. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang J, Wang L, Wang Z, Hu X, Wang B, Cao
J, Lv F, Zhen C, Zhang S and Shao Z: A phase II trial of biweekly
vinorelbine and oxaliplatin in second- or third-line metastatic
triple-negative breast cancer. Cancer Biol Ther. 16:225–232. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Laessig D, Stemmler HJ, Vehling-Kaiser U,
Fasching PA, Melchert F, Kolbl H, Stauch M, Maubach P, Scharl A,
Morack G, et al: Gemcitabine and carboplatin in intensively
pretreated patients with metastatic breast cancer. Oncology.
73:407–414. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sharma P: Biology and management of
patients with triple-negative breast cancer. Oncologist.
21:1050–1062. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dufort A and Zipursky RB: Understanding
and managing treatment adherence in schizophrenia. Clin Schizophr
Relat Psychoses. 2019 Jan 3;Online ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Whiting D, Lichtenstein P and Fazel S:
Violence and mental disorders: A structured review of associations
by individual diagnoses, risk factors, and risk assessment. Lancet
Psychiatry. 8:150–161. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhao S, Ma D, Xiao Y, Li XM, Ma JL, Zhang
H, Xu XL, Lv H, Jiang WH, Yang WT, et al: Molecular subtyping of
triple-negative breast cancers by immunohistochemistry: Molecular
basis and clinical relevance. Oncologist. 25:e1481–e1491. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tian S, Quan H, Xie C, Guo H, Lü F, Xu Y,
Li J and Lou L: YN968D1 is a novel and selective inhibitor of
vascular endothelial growth factor receptor-2 tyrosine kinase with
potent activity in vitro and in vivo. Cancer Sci. 102:1374–1380.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hu X, Zhang J, Xu B, Jiang Z, Ragaz J,
Tong Z, Zhang Q, Wang X, Feng J, Pang D, et al: Multicenter phase
II study of apatinib, a novel VEGFR inhibitor in heavily pretreated
patients with metastatic triple-negative breast cancer. Int J
Cancer. 135:1961–1969. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu J, Liu Q, Li Y, Li Q, Su F, Yao H, Su
S, Wang Q, Jin L, Wang Y, et al: Efficacy and safety of
camrelizumab combined with apatinib in advanced triple-negative
breast cancer: An open-label phase II trial. J Immunother Cancer.
8:e0006962020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu J, Wang Y, Tian Z, Lin Y, Li H, Zhu Z,
Liu Q, Su S, Zeng Y, Jia W, et al: Multicenter phase II trial of
camrelizumab combined with apatinib and eribulin in heavily
pretreated patients with advanced triple-negative breast cancer.
Nat Commun. 13:30112022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fellous A, Ohayon R, Vacassin T, Binet S,
Lataste H, Krikorian A, Couzinier JP and Meininger V: Biochemical
effects of navelbine on tubulin and associated proteins. Semin
Oncol. 16 (Suppl 4):9–14. 1989.PubMed/NCBI
|
|
18
|
Maral R, Bourut C, Chenu E and Mathé G:
Experimental antitumor activity of 5′-nor-anhydrovinblastine
navelbine. Cancer Lett. 22:49–54. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Goa KL and Faulds D: Vinorelbine. A review
of its pharmacological properties and clinical use in cancer
chemotherapy. Drugs Aging. 5:200–234. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Barni S, Freier B, Garau I, Mouysset JL,
Sediva M, Zamagni C, Berdeaux G and de Almeida Agudo C: Burden of
advanced breast cancer for patients and caregivers in Europe:
Comparison of two treatment forms of vinorelbine, oral and
intravenous. Curr Med Res Opin. 32:1807–1812. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Aapro M and Finek J: Oral vinorelbine in
metastatic breast cancer: A review of current clinical trial
results. Cancer Treat Rev. 38:120–126. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Freyer G, Delozier T, Lichinister M,
Gedouin D, Bougnoux P, His P, Imadalou K and Trillet-Lenoir V:
Phase II study of oral vinorelbine in first-line advanced breast
cancer chemotherapy. J Clin Oncol. 21:35–40. 2003.PubMed/NCBI
|
|
23
|
Mansour M and Mourad C: Phase II study of
single agent oral vinorelbine as first-line treatment in patients
with HER-2 negative metastatic breast cancer. Cancer Chemother
Pharmacol. 72:429–435. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tubiana-Mathieu N, Bougnoux P, Becquart D,
Chan A, Conte PF, Majois F, Espie M, Morand M, Vaissiere N and
Villanova G: All-oral combination of oral vinorelbine and
capecitabine as first-line chemotherapy in HER2-negative metastatic
breast cancer: An international phase II trial. Br J Cancer.
101:232–237. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nolè F, Crivellari D, Mattioli R, Pinotti
G, Foa P, Verri E, Fougeray R, Brandely M and Goldhirsch A: Phase
II study of an all-oral combination of vinorelbine with
capecitabine in patients with metastatic breast cancer. Cancer
Chemother Pharmacol. 64:673–680. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Picchioni MM and Murray RM: Schizophrenia.
BMJ. 335:91–95. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bushe CJ, Bradley AJ, Wildgust HJ and
Hodgson RE: Schizophrenia and breast cancer incidence: A systematic
review of clinical studies. Schizophr Res. 114:6–16. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Catalá-López F, Suárez-Pinilla M,
Suárez-Pinilla P, Valderas JM, Gómez-Beneyto M, Martinez S,
Balanzá-Martínez V, Climent J, Valencia A, McGrath J, et al:
Inverse and direct cancer comorbidity in people with central
nervous system disorders: A meta-analysis of cancer incidence in
577,013 participants of 50 observational studies. Psychother
Psychosom. 83:89–105. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhuo C and Triplett PT: Association of
schizophrenia with the risk of breast cancer incidence: A
meta-analysis. JAMA Psychiatry. 75:363–369. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sharma A, Ngan S, Nandoskar A, Lowdell C,
Lewis JS, Hogben K, Coombes RC and Stebbing J: Schizophrenia does
not adversely affect the treatment of women with breast cancer: A
cohort study. Breast. 19:410–412. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Regier DA, Narrow WE, Rae DS, Manderscheid
RW, Locke BZ and Goodwin FK: The de facto US mental and addictive
disorders service system. Epidemiologic catchment area prospective
1-year prevalence rates of disorders and services. Arch Gen
Psychiatry. 50:85–94. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Saha S, Chant D, Welham J and McGrath J: A
systematic review of the prevalence of schizophrenia. PLoS Med.
2:e1412005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
McGrath J, Saha S, Welham J, El Saadi O,
MacCauley C and Chant D: A systematic review of the incidence of
schizophrenia: The distribution of rates and the influence of sex,
urbanicity, migrant status and methodology. BMC Med. 2:132004.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gion M, Blancas I, Cortez-Castedo P,
Cortés-Salgado A, Marmé F, Blanch S, Morales S, Díaz N, Calvo-Plaza
I, Recalde S, et al: Atezolizumab plus paclitaxel and bevacizumab
as first-line treatment of advanced triple-negative breast cancer:
The ATRACTIB phase 2 trial. Nat Med. 31:2746–2754. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hui Y, Wang Y, Nam G, Fanion J, Sturtevant
A, Lombardo KA and Resnick MB: Differentiating breast carcinoma
with signet ring features from gastrointestinal signet ring
carcinoma: Assessment of immunohistochemical markers. Hum Pathol.
77:11–19. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu XH, Man YN, Cao R, Liu C and Wu XZ:
Individualized chemotherapy based on organ selectivity: A
retrospective study of vinorelbine and capecitabine for patients
with metastatic breast cancer. Curr Med Res Opin. 30:1017–1024.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shi J, Wu L, Zheng W, Wen W, Wang S, Shu
X, Long J, Shen CY, Wu PE, Saloustros E, et al: Genetic evidence
for the association between schizophrenia and breast cancer. J
Psychiatr Brain Sci. 3:72018.PubMed/NCBI
|
|
38
|
Hwang M, Farasatpour M, Williams CD,
Margenthaler JA, Virgo KS and Johnson FE: Adjuvant chemotherapy for
breast cancer in patients with schizophrenia. Oncol Lett.
3:845–850. 2012.PubMed/NCBI
|